Summary:
A Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Lumateperone: Monotherapy in the Treatment of Patients with Major Depressive Episodes or have Associated depressive episodes with Bipolar I or Bipolar II Disorder (Bipolar Depression)
Who is Qualified?:
- Participants who are generally healthy and between 18-75 years old.
- Participants who have been in a depressive episode for at least 2 weeks but not more than 6 months. (Recurrent depressive symptoms are ok if you have 6-8 good weeks in between each episode.)
- No medication history necessary to qualify.
- No previous diagnosis needed to qualify.
- Insurance not required to qualify.
- Participants willing to stop all psychiatric medications they are currently taking.
- Diagnosis of just depression or any type of Bi-Polar is allowed.
Qualified Participants Can Receive:
- $50 in Compensation after each completed appointment.
- Travel or gas reimbursement up to $53 per visit.
- Lumateperone medication at no cost. (FDA approved but not yet for the treatment of depressive symptoms.)
- Free labs and blood work during the initial visit and through the study.
How long are these studies?
- This study is 10-12 Weeks long with 9 scheduled visits at our office in Oceanside.
- Studies are voluntary in the sense that you can stop at any moment; You are paid after each completed appointment $50 plus transportation reimbursement up to $53 per visit.
- Each visit will be about an hour besides the initial screening visit which is normally 4-5 hours.